CANCER:

Lung Cancer

EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	DZD9008 Sensitive: B - Late Trials PRNewswire - 1 day	DZD9008 Sensitive: B - Late Trials PRNewswire - 1 day
EGFR mutation + S100A9 overexpression EGFR mutation + S100A9 overexpression	Lung Cancer Lung Cancer	EGFR mutation + S100A9 overexpression EGFR mutation + S100A9 overexpression	Lung Cancer Lung Cancer	osimertinib Resistant: D – Preclinical Cancer Discov - 3 days	osimertinib Resistant: D – Preclinical Cancer Discov - 3 days
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval Amgen Press Release - 1 week	sotorasib Sensitive: A1 - Approval Amgen Press Release - 1 week
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: B - Late Trials Regeneron Pharmaceuticals Press Release - 1 week	cemiplimab Sensitive: B - Late Trials Regeneron Pharmaceuticals Press Release - 1 week
PD-L1 negative PD-L1 negative	Non Small Cell Lung Cancer NSCLC	PD-L1 negative PD-L1 negative	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
IL6 underexpression IL6 underexpression	Non Small Cell Lung Cancer NSCLC	IL6 underexpression IL6 underexpression	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
CSF1 underexpression CSF1 underexpression	Non Small Cell Lung Cancer NSCLC	CSF1 underexpression CSF1 underexpression	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
CCL23 underexpression CCL23 underexpression	Non Small Cell Lung Cancer NSCLC	CCL23 underexpression CCL23 underexpression	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week	ABBV-181 Sensitive: C3 – Early Trials J Immunother - 1 week
KRT7 positive + NKX2-1 positive + ALK overexpression KRT7 positive + NKX2-1 positive + ALK overexpression	Lung Cancer Lung Cancer	KRT7 positive + NKX2-1 positive + ALK overexpression KRT7 positive + NKX2-1 positive + ALK overexpression	Lung Cancer Lung Cancer	alectinib Sensitive: C4 – Case Studies Case Rep Oncol - 1 week	alectinib Sensitive: C4 – Case Studies Case Rep Oncol - 1 week
EGFR negative + ALK overexpression EGFR negative + ALK overexpression	Lung Cancer Lung Cancer	EGFR negative + ALK overexpression EGFR negative + ALK overexpression	Lung Cancer Lung Cancer	alectinib Sensitive: C4 – Case Studies Case Rep Oncol - 1 week	alectinib Sensitive: C4 – Case Studies Case Rep Oncol - 1 week
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	sintilimab Sensitive: C3 – Early Trials NPJ Precis Oncol - 2 weeks	sintilimab Sensitive: C3 – Early Trials NPJ Precis Oncol - 2 weeks
ALK-EML4_V3b + PD-L1 Overexpression ALK-EML4_V3b + PD-L1 Overexpression	Non Small Cell Lung Cancer NSCLC	ALK-EML4_V3b + PD-L1 Overexpression ALK-EML4_V3b + PD-L1 Overexpression	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Lung Cancer - 2 weeks	ALK inhibitor Resistant: C3 – Early Trials Lung Cancer - 2 weeks
ALK-EML4_V3a + PD-L1 Overexpression ALK-EML4_V3a + PD-L1 Overexpression	Non Small Cell Lung Cancer NSCLC	ALK-EML4_V3a + PD-L1 Overexpression ALK-EML4_V3a + PD-L1 Overexpression	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Lung Cancer - 2 weeks	ALK inhibitor Resistant: C3 – Early Trials Lung Cancer - 2 weeks
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval BeiGene Press Release - 3 weeks	tislelizumab Sensitive: A1 - Approval BeiGene Press Release - 3 weeks
PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 expression PD-L1 expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline PharmiWeb - 3 weeks	pembrolizumab Sensitive: A2 - Guideline PharmiWeb - 3 weeks
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	CLN-081 Sensitive: B - Late Trials Cullinan Oncology - 3 weeks	CLN-081 Sensitive: B - Late Trials Cullinan Oncology - 3 weeks
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials Genprex Press Release - 3 weeks	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials Genprex Press Release - 3 weeks
EGFR wild-type + MET overexpression EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: B - Late Trials AbbVie Press Release - 3 weeks	ABBV-399 Sensitive: B - Late Trials AbbVie Press Release - 3 weeks
EGFR L747P EGFR L747P	Lung Adenocarcinoma LUAD	EGFR L747P EGFR L747P	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C4 – Case Studies Anticancer Res - 3 weeks	erlotinib Sensitive: C4 – Case Studies Anticancer Res - 3 weeks
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks	Immunotherapy Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks	Immunotherapy Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks
DCTN1-ALK fusion DCTN1-ALK fusion	Lung Adenocarcinoma LUAD	DCTN1-ALK fusion DCTN1-ALK fusion	Lung Adenocarcinoma LUAD	alectinib Sensitive: C4 – Case Studies Thorac Cancer - 4 weeks	alectinib Sensitive: C4 – Case Studies Thorac Cancer - 4 weeks
EGFR exon 19 deletion + EGFR T790M EGFR exon 19 deletion + EGFR T790M	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR T790M EGFR exon 19 deletion + EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C4 – Case Studies Thorac Cancer - 4 weeks	osimertinib Sensitive: C4 – Case Studies Thorac Cancer - 4 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval	ramucirumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval J Thorac Oncol - 2 weeks	lorlatinib Sensitive: A1 - Approval J Thorac Oncol - 2 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval Cancer Med - 2 weeks	osimertinib Sensitive: A1 - Approval Cancer Med - 2 weeks
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval	alectinib Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval	tepotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval Cancer Med - 2 weeks	dacomitinib Sensitive: A1 - Approval Cancer Med - 2 weeks
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval Cancer Med - 2 weeks	dacomitinib Sensitive: A1 - Approval Cancer Med - 2 weeks
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval	capmatinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval Int J Gen Med - 1 week	gefitinib Sensitive: A1 - Approval Int J Gen Med - 1 week
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval NICE - 2 weeks	selpercatinib Sensitive: A1 - Approval NICE - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	mobocertinib Sensitive: A1 - Approval	mobocertinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval	DP Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval	topotecan Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval	lurbinectedin Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval	amivantamab-vmjw Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: A1 - Approval	aumolertinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	sugemalimab Sensitive: A1 - Approval	sugemalimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval

Lung Cancer

Associations(2619)

Associations
(2619)